Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum CECT 9422 + bifidobacterium longum CECT 30257
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum CECT 9422 + Bifidobacterium longum CECT 30257 is a probiotic combination developed by AB-Biotics (a Kaneka company) for the management of infant colic and functional gastrointestinal disorders. The formulation consists of two specific bacterial strains: *Lactiplantibacillus plantarum* (formerly *Lactobacillus plantarum*) CECT 9422 and *Bifidobacterium longum* CECT 30257. These strains were selected for their ability to survive gastrointestinal transit, adhere to the intestinal mucosa, and inhibit the growth of gas-producing bacteria such as *Enterobacteriaceae*. Clinical studies have demonstrated that this combination significantly reduces daily crying and fussing time in colicky infants by modulating the gut microbiota and potentially exerting anti-inflammatory effects. It is primarily marketed as a dietary supplement to support digestive health in neonates and infants.
- Brand names
- KolicareAB-Kolicare
- Other names
- Lactobacillus CECT 9422 + Bifidobacterium CECT 30257Lactiplantibacillus plantarum CECT 9422 + Bifidobacterium longum CECT 30257L. plantarum CECT 9422 + B. longum CECT 30257
Beyond the preview
Go deeper on lactobacillus plantarum CECT 9422 + bifidobacterium longum CECT 30257.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum CECT 9422 + bifidobacterium longum CECT 30257.